Zhang Feng, Yang Meiming, Xiao Ting, Hua Yan, Chen Yu, Xu Shasha, Ni Chunping
School of Nursing, Air Force Military Medical University, Xi'an, Shaanxi Province, China.
Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi Province, China.
J Int Med Res. 2020 Sep;48(9):300060520935309. doi: 10.1177/0300060520935309.
To investigate the association between the solute carrier family 6 member 4 () gene L/S polymorphism and pulmonary arterial hypertension (PAH).
The relevant literature was retrieved from the PubMed® database and the data were extracted. STATA® version 12.0 software was used to calculate pooled odds ratios (ORs) and 95% confidence intervals (CI).
Eight case-control studies qualified for inclusion in the meta-analysis. These studies included 1215 cases and 936 control subjects. There was no significant association between the gene L/S polymorphism and PAH risk in the total population (LL versus SS: OR 1.83, 95% CI 0.95, 3.51; LS versus SS: OR 1.37, 95% CI 0.93, 2.02; dominant model: OR 1.38, 95% CI 0.97, 1.97; recessive model: OR 1.54, 95% CI 0.84, 2.83). Subgroup analysis based on study quality scores and Hardy-Weinberg equilibrium also showed no significant association.
The findings of this meta-analysis suggest that the gene L/S polymorphism is unlikely to be related to PAH risk. Well-designed studies with more participants will be required to validate these results.
探讨溶质载体家族6成员4（）基因L/S多态性与肺动脉高压（PAH）之间的关联。
从PubMed®数据库检索相关文献并提取数据。使用STATA® 12.0软件计算合并比值比（OR）和95%置信区间（CI）。
八项病例对照研究符合纳入荟萃分析的条件。这些研究包括1215例病例和936例对照。在总体人群中，基因L/S多态性与PAH风险之间无显著关联（LL与SS比较：OR 1.83，95%CI 0.95，3.51；LS与SS比较：OR 1.37，95%CI 0.93，2.02；显性模型：OR 1.38，95%CI 0.97，1.97；隐性模型：OR 1.54，95%CI 0.84，2.83）。基于研究质量评分和哈迪-温伯格平衡的亚组分析也未显示出显著关联。
这项荟萃分析的结果表明，基因L/S多态性不太可能与PAH风险相关。需要设计更完善、纳入更多参与者的研究来验证这些结果。
